As competitive as the obesity drug market has become, Novo Nordisk's decision to slash the prices of its GLP-1 agonist drugs ...

Telehealth company Hims & Hers Health Inc. said late Monday it is in “active discussions” with Denmark’s Novo Nordisk A/S to make Wegovy available on its platform. The discussions are about both ...

Novo Nordisk stock price has suffered a harsh reversal this year as the company’s woes have escalated. What next for the stock?

・Retail traders ranked Novo Nordisk as the strongest long-term obesity play in a 1,100-vote poll. ・Users pointed to emerging ...

Danish drugmaker Novo Nordisk A/S was at the forefront of the weight-loss injection boom as people discovered that its ...

Hims & Hers shows platform expansion, verticalization, new Labs offerings, slower FCF growth and strong long-term revenue ...

The company said it was in active discussion with Novo Nordisk to bring back Wegovy to its platform. The stock looks attractively priced at current levels, given its growth outlook. 10 stocks we like ...

Hims & Hers Health has appointed Deb Autor as its first chief policy officer to lead public policy and government functions, the telehealth firm said on Monday.

Within the healthcare space, one company that combines fundamental safety with the high growth rates typically found in ...

The Denmark-based company on Monday said it will offer the first two monthly doses of Wegovy and Ozempic for $199 a month to those who pay in cash between now and March 31 of next year. After those ...